| Date | Acquired company | Acquiring company | Amount | Related |
|---|---|---|---|---|
| 2019-02-13 | Citoxlab (France) | Charles River Laboratories (USA - MA) | €448 million | Technology - Services |
| 2019-01-25 | Apricus Therapeutics (USA - CA) | Seelos Therapeutics (USA - NY) | CNS diseases - Rheumatic diseases | |
| 2019-01-25 | Capua BioServices (Italy)) | Olon (Italy)) | CDMO - Technology - Services | |
| 2019-01-23 | MAB Discovery's antibody generation unit (Germany) | BioNTech (Germany) | undisclosed | Technologies - Services |
| 2019-01-22 | Tesaro (USA - MA) | GSK (UK) | $5.1 billion (£4.0 billion) | Cancer - Oncology |
| 2019-01-07 | Loxo Oncology (USA - CT) | Eli Lilly (USA - IN) | $ 8 billion | Cancer - Oncology |
| 2019-01-06 | Celgene (USa - NJ) | BMS (USA - NY) | $74 billion | Cancer - Oncology - Cardiovascular diseases - Immunological diseases - Inflammatory diseases |
| 2019-01-04 | Oncotelix | Mabvax | Cancer - Digestive diseases | |
| 2018-12-31 | Tonipharm (France) | Recordati (Italy) | OTC | |
| 2018-12-21 | Endocyte (USA - IN) | Novartis (Switzerland) | $ 2.1 billion | Cancer - Oncology |
| 2018-12-20 | Cellforcure (France) | Novartis (Switzerland) | CDMO - | |
| 2018-12-06 | Recordati (Italy) | CVC Fund VII | €3.03 billion | |
| 2018-11-02 | Syntimmune (USA - MA) | Alexion Pharmaceuticals (USA - CT) | up to $1.2 billion | |
| 2018-10-26 | Shire (UK - USA) | Takeda Pharmaceutical (Japan) | $ 62 billion | Gastroinstestinal diseases - Neurosciences - Rare diseases - Genetic diseases - Immunological diseases |
| 2018-10-09 | Vector Neurosciences (UK) | MeiraGTx (USA - NY) | Neurodegenerative diseases - CNS diseases | |
| 2018-10-04 | PaxVax (USA - CA) | Emergent BioSolutions (USA - MD) | $270 million | Infectious diseases |
| 2018-10-01 | Sanofi’s inhalation contract manufacturing business | Recipharm (Sweden) | undisclosed | Technology - Services |
| 2018-09-26 | Syntimmune (USA - MA) | Alexion Pharmaceuticals (USA -MA) | up to $1.2 billion | Autoimmune diseases |
| 2018-09-20 | Celenex | Amicus Therapeutics (USA - NJ) | $100 million in an upfront cash payment and up to $15 million in development milestones and $262 million in BLA/MAA submission and approval milestones | Gene Therapy - Rare diseases - CNS diseases |
| 2018-09-14 | Bonti (USA - CA) | Allergan (Ireland) | $195 million and additional potential commercial milestone payments, subject to certain adjustments and other customary closing conditions | aesthetic medicine |
